![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by jrbecker on September 29, 2005, at 9:36:01
http://news.yahoo.com/s/nm/20050929/hl_nm/lilly_dc
Lilly adds suicide risk to Strattera
Eli Lilly and Co. on Thursday said it will add strong warnings to its label for Strattera, used to treat attention-deficit/hyperactivity disorder, including the risk of suicidal thoughts among children and adolescents.Strattera will now carry a "black box" warning, the strongest required by U.S. regulators.
Lilly said there were no suicides among children, adolescents or adults taking the medication during Strattera clinical trials, but there was one suicide attempt in a patient taking the drug.
The warning came after the U.S. Food and Drug Administration requested Lilly to submit an analysis of adverse event data from its Strattera clinical trials data base, which identified a small but statistically significant increased risk of suicidal thoughts among Strattera-treated children and adolescents.
Lilly said it is working with the FDA to finalize the product label. It also is working with regulators outside the United States.
Lilly backed its prior sales and earnings outlook for the year and said it expects to report full-year 2005 earnings per share of $1.90 to $1.96.
ADHD affects 3 to 7 percent of school-age children and manifests itself in inappropriate levels of attention, concentration, activity, distractibility and impulsivity.
Shares of Lilly closed at $53.47 on Wednesday on the New York Stock Exchange.
Posted by Cairo on September 29, 2005, at 21:02:39
In reply to Lilly adds suicide risk to Strattera, posted by jrbecker on September 29, 2005, at 9:36:01
Strattera definitely caused a first bout of major depression in my teen daughter, even at a relatively low dose. Weaned her off even before we had our next appointment with the pdoc and her mood improved. I guess that means caution for anything with an NRI component.
Would this suggest Chrousos' theory of high CRH/NE in some types of depression?
Cairo
> http://news.yahoo.com/s/nm/20050929/hl_nm/lilly_dc
>
> Lilly adds suicide risk to Strattera
>
> Eli Lilly and Co. on Thursday said it will add strong warnings to its label for Strattera, used to treat attention-deficit/hyperactivity disorder, including the risk of suicidal thoughts among children and adolescents.
>
> Strattera will now carry a "black box" warning, the strongest required by U.S. regulators.
>
> Lilly said there were no suicides among children, adolescents or adults taking the medication during Strattera clinical trials, but there was one suicide attempt in a patient taking the drug.
>
> The warning came after the U.S. Food and Drug Administration requested Lilly to submit an analysis of adverse event data from its Strattera clinical trials data base, which identified a small but statistically significant increased risk of suicidal thoughts among Strattera-treated children and adolescents.
>
> Lilly said it is working with the FDA to finalize the product label. It also is working with regulators outside the United States.
>
> Lilly backed its prior sales and earnings outlook for the year and said it expects to report full-year 2005 earnings per share of $1.90 to $1.96.
>
> ADHD affects 3 to 7 percent of school-age children and manifests itself in inappropriate levels of attention, concentration, activity, distractibility and impulsivity.
>
> Shares of Lilly closed at $53.47 on Wednesday on the New York Stock Exchange.
>
>
Posted by zeugma on September 30, 2005, at 17:25:49
In reply to Re: Lilly adds suicide risk to Strattera, posted by Cairo on September 29, 2005, at 21:02:39
I don't think that Strattera is necessarily typical of NRI's. I have done very well on nortriptyline for years. Strattera induced a severe, anhedonic depression. Even before it induced depression, it felt subjectively very different, much more like a stimulant. I am one of those who has suffered from stim dysphoria at certain times.
-z
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.